MGI Tech Launches VisiOmics in Europe, Unveils AI Pathology Portfolio
MGI Tech has launched its VisiOmics solution in Europe and unveiled its new AI-enabled pathology portfolio at the ECP 2026 congress. The company focuses on integrated solutions for tissue and molecular pathology, from sample to result.
MGI Tech Co., Ltd. (MGI) has expanded its reach into the European market with the launch of its VisiOmics solution. The company also presented its new AI-enabled pathology portfolio at the European Congress of Pathology (ECP) 2026. MGI Tech aims to provide integrated solutions for tissue and molecular pathology analysis.
The new offerings cover the entire workflow, from sample preparation and multiplex immunofluorescence to sequencing and result generation. Artificial intelligence is a key component, designed to accelerate data analysis and enhance diagnostic accuracy in pathology.
MGI Tech's objective is to supply comprehensive tools and technologies that support research and diagnostics within the pathology field. The company states that the VisiOmics solution facilitates a more rapid and efficient process for obtaining accurate results from tissue samples.
The ECP 2026 congress provided a venue for MGI Tech to showcase its latest advancements and engage with industry professionals. Moving forward, the company intends to further develop AI-driven solutions to improve pathology diagnostics.